NCT06738017
AATD, Alpha 1-Antitrypsin Deficiency
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.
Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters.
Participants will receive a single dose of either BMN 349 or placebo and then monitored for safety and tolerability.
All
18 Years to 75 Years
No
BMN 349, Placebo
Phase 1
Interventional
12
2025-02-21
2025-07-24
San Diego, California, United States
Trial Status Recruiting
Egbert Madamba
858-246-2227 emadamba@health.ucsd.edu
St Louis, Missouri, United States
Trial Status Recruiting
Jeffery Teckman Principal Investigator, MD
314-577-5647 jeff.teckman@health.slu.edu
Cincinnati, Ohio, United States
Trial Status Recruiting
Tina M Ramey
513-579-9911 recruitment@medpace.com
Charleston, South Carolina, United States
Trial Status Recruiting
Kristin Neff Primary CRC
843-792-1219 neffk@musc.edu
Edinburgh, UK, United Kingdom
Trial Status Not yet recruiting
Ellyse Kilarski
+44 (0131) 242 1289 Ellyse.Kilarski@nhs.scot
London, UK, United Kingdom
Trial Status Recruiting
Nottingham, UK, United Kingdom
Trial Status Not yet recruiting
Stephen Ryder, MD
+44(0)115 9249924 stephen.ryder@nuh.nhs.uk
Southampton, UK, United Kingdom
Trial Status Not yet recruiting
AATD Research Team
023 8120 4479 AATDService@uhs.nhs.uk
*required fields
"*" indicates required fields